Manager TitleAgeSince
President - 14/12/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 14/12/2023
Director/Board Member - 14/12/2023
Date Insider Type Main position Quantity % Market Cap.
14/12/23 Issuer sale

Director

127,934 0.0678%
14/12/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
14/12/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-0.14%+0.14%-0.81%+13.79% 48.22B
-2.71%-2.99%+398.09%+472.12% 38.79B
-0.71%+9.45%+27.90%+7.89% 38.41B
-0.71%-3.72%+4.94%+52.45% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.66%-2.73%+35.50%+122.17% 16B
-0.19%-3.93% - - 16.05B
+1.77%+0.64%+3.64%+17.04% 13.53B
-3.15%-6.14%-4.82%-36.90% 12.22B
Average -0.55%-0.66%+59.51%+85.84% 27.48B
Weighted average by Cap. -0.45%+0.15%+75.87%+103.61%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock